Page last updated: 2024-11-08

sq 27860

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carbapenem-3-carboxylic acid: from species of Serratia & Erwinia; carbapenam antibiotic; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-carbapenem-3-carboxylic acid : A carbapenemcarboxylic acid that is the 3-carboxy derivative of 2,3-didehydro-1-carbapenam. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441133
CHEMBL ID1240705
CHEBI ID615
SCHEMBL ID8106876
MeSH IDM0109075

Synonyms (26)

Synonym
C06669
(5r)-carbapenem-3-carboxylic acid
1-carbapen-2-em-3-carboxylic acid
carbapenem-3-carboxylic acid
1-carbapenem-3-carboxylic acid
sq 27860
2,3-didehydro-1-carbapenam-3-carboxylic acid
(5r)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
CHEBI:615 ,
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 7-oxo-
antibiotic tan 458
sq-27860
(5r)-carbapenem
CHEMBL1240705
carbapenem, (5r)-
78854-41-8
SCHEMBL8106876
antibiotic tan
gl970841ys ,
sq 27,860
sq-27,860
unii-gl970841ys
(5r)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 7-oxo-, (5r)-
Q27105319
DTXSID401192165
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
carbapenemcarboxylic acid
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID508481Antimicrobial activity against Pseudomonas aeruginosa isolate B4-25753 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508483Antimicrobial activity against Pseudomonas aeruginosa isolate K34-7 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508485Antimicrobial activity against Pseudomonas aeruginosa isolate BU-43038 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508484Antimicrobial activity against Pseudomonas aeruginosa isolate BU-20287 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508482Antimicrobial activity against Pseudomonas aeruginosa isolate K34-73 producing metallo-beta-lactamase VIM4 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508489Antimicrobial activity against Pseudomonas aeruginosa isolate K44-24 producing metallo-beta-lactamase IMP14 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID529517Antibacterial activity against Pseudomonas aeruginosa isolates by Etest2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID508486Antimicrobial activity against Pseudomonas aeruginosa isolate BU-36178 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508479Antimicrobial activity against Pseudomonas aeruginosa isolate PA66 producing metallo-beta-lactamase VIM4 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508480Antimicrobial activity against Pseudomonas aeruginosa isolate AK5493 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508478Antimicrobial activity against Pseudomonas aeruginosa isolate U9-19005 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508490Antimicrobial activity against Pseudomonas aeruginosa isolate K45-32 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID529515Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest in presence of EDTA2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID508487Antimicrobial activity against Pseudomonas aeruginosa isolate BNL-1681 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID508488Antimicrobial activity against Pseudomonas aeruginosa isolate OS-210 producing metallo-beta-lactamase VIM2 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's2 (22.22)18.2507
2000's4 (44.44)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (11.11%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]